Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies targeting the complement system, a key part of the immune system implicated in a range of rare, serious, and life‑threatening diseases. The company operates within the biotechnology and pharmaceuticals industries, with a particular emphasis on rare diseases, hematology, and ophthalmology. Apellis’ core scientific approach centers on inhibiting complement component C3, which allows for broad upstream control of the complement cascade.
The company’s primary revenue drivers are its approved complement inhibitor therapies, notably EMPAVELI® (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH) and SYFOVRE® (pegcetacoplan injection) for geographic atrophy secondary to age-related macular degeneration. Apellis serves specialist-driven markets, including hematologists and retinal specialists, primarily in the United States and select international markets. Founded in 2009, Apellis evolved from a clinical-stage biotechnology company into a commercial organization following regulatory approvals in the early 2020s, marking a strategic shift toward sustained product commercialization.
Business Operations
Apellis generates revenue primarily through the sale of its approved therapies in the U.S. market, supplemented by collaboration and licensing arrangements in international territories. Its operations are organized around two main therapeutic areas: hematology and ophthalmology, both leveraging the company’s proprietary C3 inhibition platform. Research and development activities remain a significant operational focus, supporting both lifecycle management of existing products and advancement of pipeline candidates.
The company controls key intellectual property related to pegcetacoplan and other complement inhibitors, including proprietary peptide chemistry and delivery technologies. Apellis conducts clinical development internally while relying on third-party manufacturers for commercial supply. Internationally, Apellis has entered into strategic partnerships for commercialization outside the United States, most notably with Swedish Orphan Biovitrum AB (Sobi) for certain ex‑U.S. markets, allowing the company to extend global reach without building a fully integrated international sales infrastructure.
Strategic Position & Investments
Apellis’ strategy is centered on establishing leadership in complement biology, with an emphasis on first‑ or best‑in‑class therapies addressing high unmet medical needs. Growth initiatives include expanding indications for existing products, advancing next‑generation complement inhibitors, and strengthening commercial execution in ophthalmology following the launch of SYFOVRE®. The company continues to invest heavily in clinical trials to support label expansion and longer‑term pipeline sustainability.
Key investments have focused on internal research capabilities rather than large-scale acquisitions, with capital allocation directed toward clinical development, manufacturing scale-up, and post‑marketing commitments. Apellis maintains several development‑stage programs targeting additional complement‑mediated diseases, including earlier‑stage ophthalmic and systemic indications. Data regarding specific future acquisitions or unannounced strategic transactions is inconclusive based on available public sources.
Geographic Footprint
Apellis Pharmaceuticals is headquartered in the United States, with its principal executive offices in Waltham, Massachusetts. The company’s primary commercial presence is in North America, where it conducts the majority of its sales, marketing, and clinical activities. Research and corporate functions are also largely centralized in the U.S., supporting operational efficiency and regulatory engagement.
Internationally, Apellis maintains a presence through strategic collaborators and partners across Europe and other select regions. These partnerships enable market access, regulatory filings, and distribution without extensive owned infrastructure abroad. While Apellis does not operate large standalone international subsidiaries for commercial sales, its therapies have a growing global footprint through licensed and partnered arrangements.
Leadership & Governance
Apellis is led by an experienced executive team with deep backgrounds in biotechnology, rare disease commercialization, and drug development. The company emphasizes a leadership philosophy centered on scientific rigor, patient‑focused innovation, and disciplined capital deployment. Governance practices align with U.S. public company standards, with oversight provided by an independent board of directors.
Key executives include:
- Cedric Francois – Chief Executive Officer and Co‑Founder
- Adam Scott – Chief Financial Officer
- Jennifer Cook – Chief Legal Officer and Corporate Secretary
- Brian G. Smith – Chief Commercial Officer
- Kristin Yarema – Chief Development Officer
The leadership team collectively drives Apellis’ strategic vision to build a sustainable, innovation‑driven biopharmaceutical company anchored in complement science.